Dataset from A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

The purpose of this study is to determine if the addition of apalutamide to ADT provides
superior efficacy in improving radiographic progression-free survival (rPFS) or overall
survival (OS) for participants with mHSPC.

本研究旨在明确在雄激素剥夺治疗（Androgen Deprivation Therapy, ADT）基础上加用阿帕他胺（apalutamide），是否可使转移性去势敏感性前列腺癌（metastatic hormone-sensitive prostate cancer, mHSPC）患者获得更优疗效，进而改善其影像学无进展生存期（radiographic progression-free survival, rPFS）与总生存期（overall survival, OS）。